Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Champlin

Showing results (591-600 of 671) with videos related to

Pageof 68
Sort By:
Immunohorizons|June 8, 2023
A Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus-Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation: Proof of ConceptEdwin J Ostrin, Nicholas L Rider, Amin M Alousi, et al.
American Journal of Hematology|October 10, 2019
Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantationSamer A Srour, Rima M Saliba, Maria C B Bittencourt, et al.
Blood Advances|September 13, 2018
Is a matched unrelated donor search needed for all allogeneic transplant candidates?Stefan O Ciurea, Maria Cecilia Borges Bittencourt, Denái R Milton, et al.
Transplantation and Cellular Therapy|January 16, 2023
Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center ExperienceOren Pasvolsky, Mahmoud R Gaballa, Denái R Milton, et al.
British Journal of Haematology|July 6, 2026
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myelomaCurtis Marcoux, Denái R Milton, Mark R Tanner, et al.
Blood Advances|December 3, 2021
Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivoXiaoshan Zhang, Ran Zhang, Chenghui Ren, et al.
Transplantation and Cellular Therapy|March 25, 2022
Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell TransplantationAimaz Afrough, Oren Pasvolsky, Junsheng Ma, et al.
Blood Cancer Journal|January 10, 2024
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experienceOren Pasvolsky, Sassine Ghanem, Denái R Milton, et al.
Transplantation and Cellular Therapy|June 9, 2024
Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three DecadesOren Pasvolsky, Curtis Marcoux, Jianliang Dai, et al.
Blood|June 11, 2021
Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemiaTomoyuki Tanaka, Kiyomi Morita, Sanam Loghavi, et al.
Pageof 68

Showing results (591-600 of 671) with videos related to

Sort By:
Pageof 68
Immunohorizons|June 8, 2023
A Nasal Inflammatory Cytokine Signature Is Associated with Early Graft-versus-Host Disease of the Lung after Allogeneic Hematopoietic Cell Transplantation: Proof of ConceptEdwin J Ostrin, Nicholas L Rider, Amin M Alousi, et al.
American Journal of Hematology|October 10, 2019
Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantationSamer A Srour, Rima M Saliba, Maria C B Bittencourt, et al.
Blood Advances|September 13, 2018
Is a matched unrelated donor search needed for all allogeneic transplant candidates?Stefan O Ciurea, Maria Cecilia Borges Bittencourt, Denái R Milton, et al.
Transplantation and Cellular Therapy|January 16, 2023
Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center ExperienceOren Pasvolsky, Mahmoud R Gaballa, Denái R Milton, et al.
British Journal of Haematology|July 6, 2026
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myelomaCurtis Marcoux, Denái R Milton, Mark R Tanner, et al.
Blood Advances|December 3, 2021
Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivoXiaoshan Zhang, Ran Zhang, Chenghui Ren, et al.
Transplantation and Cellular Therapy|March 25, 2022
Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell TransplantationAimaz Afrough, Oren Pasvolsky, Junsheng Ma, et al.
Blood Cancer Journal|January 10, 2024
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experienceOren Pasvolsky, Sassine Ghanem, Denái R Milton, et al.
Transplantation and Cellular Therapy|June 9, 2024
Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three DecadesOren Pasvolsky, Curtis Marcoux, Jianliang Dai, et al.
Blood|June 11, 2021
Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemiaTomoyuki Tanaka, Kiyomi Morita, Sanam Loghavi, et al.
Pageof 68